Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024.
Antunes L, Rojas-Castro M, Lozano M, Martínez-Baz I, Leroux-Roels I, Borg ML, Oroszi B, Fitzgerald M, Dürrwald R, Jancoriene L, Machado A, Petrović G, Lazar M, Součková L, Bacci S, Howard J, Verdasca N, Basile L, Castilla J, Ternest S, Džiugytė A, Túri G, Duffy R, Hackmann C, Kuliese M, Gomez V, Makarić ZL, Marin A, Husa P, Nicolay N, Rose AMC; VEBIS SARI VE network team.
Antunes L, et al.
Influenza Other Respir Viruses. 2025 Mar;19(3):e70081. doi: 10.1111/irv.70081.
Influenza Other Respir Viruses. 2025.
PMID: 40059069
Free PMC article.